Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.-MedSci.cn

Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.

Gelderblom, H; Tap, WD; Palmerini, E; Stacchiotti, S; Wainberg, ZA; Desai, J; Healey, JH; van de Sande, M; Bernthal, NM; Peterfy, C; Shuster, DE; Wang, Q; Hsu, H; Wagner, AJ

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务